drugset / Trial / NCT03537690
FID-007 in Treating Participants With Advanced Solid Tumors
Phase 1
Active not recruiting
50 enrolled
University of Southern California
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of PEOX-based polymer encapsulated paclitaxel FID-007 (FID-007) in treating participants with malignant neoplasms that have spread to other places in the body and do not respond to treatment. FID-007 is a packaged form of the chemotherapy drug paclitaxel, and uses a polyethylozaxoline (PEOX) polymer which may allow the drug to reach deeper into tumors and less into normal cells by being smaller.
Timeline
- Start
- 2018-05-25
- Primary completion
- 2026-12-31
- Completion
- 2027-05-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | — | Intravenous |